►
From YouTube: Smart Contracts and Petri Dishes: Creating a Shared Technical Infrastructure Roadmap for DeSci
Description
Visit the https://archive.devcon.org/ to gain access to the entire library of Devcon talks with the ease of filtering, playlists, personalized suggestions, decentralized access on Swarm, IPFS and more.
https://archive.devcon.org/archive/watch/6/smart-contracts-and-petri-dishes-creating-a-shared-technical-infrastructure-roadmap-for-descentralised-science-desci-on-ethereum/
DeSci is the combination of open science principles and decentralization. This workshop aims to unite founders and developers in the DeSci ecosystem to explore what infrastructure is needed: from reputation systems for scientific credentials, to file storage, public good funding and financialisation. Participants will actively determine pressing needs and a roadmap to functioning DeSci dapps, while also exploring the cultural complexity and UX of scientists as a user group.
Speaker(s): Paul Kohlhaas
Track: Developer Infrastructure
Keywords: Tooling,DeSci,Data
Follow us: https://twitter.com/efdevcon, https://twitter.com/ethereum
Learn more about devcon: https://www.devcon.org/
Learn more about ethereum: https://ethereum.org/
Devcon is the Ethereum conference for developers, researchers, thinkers, and makers.
Devcon 6 was held in Bogotá, Colombia on Oct 11 - 14, 2022.
Devcon is organized and presented by the Ethereum Foundation, with the support of our sponsors. To find out more, please visit https://ethereum.foundation/
A
A
Is
my
contract
in
Petri
dishes
essentially
merging
these
two
Fields
together
and
then
with
a
goal
to
who
everyone
is
here
today
to
kind
of
look
at
beginning
to
create
a
shared
technical
infrastructure
roadmap
for
what
is
actually
required
to
make
DSi
a
success
cool?
So
we
saw
some
people
coming
in
maybe
a
few
words
about
myself,
hi
everyone.
My
name
is
Paula
cohass
I'm,
the
CEO
and
co-founder
of
a
company
and
ecosystem
protocol
called
molecule
and
I.
A
Had
the
amazing
opportunity
last
year
to
work
with
a
great
group
of
people
to
launch
one
of
the
first
desai-centric
research
organizations
called
read
of
that.
Maybe
maybe
just
start
with
that,
like
maybe
a
show
of
hands
who's
heard
of
vidad,
okay,
so
almost
pretty
much
everyone.
It
was
a
little
bit
hard
for
me
to
gauge
the
audience
of
this.
A
I,
actually
don't
have
a
background
in
science,
but
rather
in
economics.
Traditionally,
however,
science
and
specifically
like
biotech,
has
been
a
huge
personal
hobby
of
mine,
since
my
teenagers
I
spent
a
lot
of
time
in
in
online
biohacking
communities
as
a
teenager,
and
some
of
you
may
be
familiar
with
these
there's.
A
All
of
these
different
subreddits
focused
on
nootropics,
for
example,
or
biohacking,
and
so
as
a
teenager
I
spent
kind
of
time
in
in
these
online
communities
that
were,
for
example,
diabetics
and
that
we're
looking
at
alternative
ways
of
accessing
insulin.
As
many
of
you
probably
know,
incident
prices
in
the
United
States
have
skyrocketed
over
the
past
over
the
past
decade,
and
so
these
communities
were
looking
at
ways
of
producing
their
own
insulin
kind
of
in
in
a
garage
which
sounds
super
risky.
A
But
actually
often
people
are
our
current
Healthcare
System,
really
like
underserved
certain
patient
population,
similar
cases
in,
for
example,
in
different
HIV
communities
that
we're
kind
of
collaborating
online
to
develop
their
own
open
source,
Gene
therapies
or
in
other
cases
you
have
communities
of
psychedelic
researchers
and
enthusiasts
that
are
kind
of
exploring
hundreds
of
different
novel
psychedelic
compounds.
So
what
happened
in
these
communities?
Someone
would
say:
hey
here's,
an
interesting
chemical
structure,
I
think
it
could
do
this.
Doesn't
this
in
the
human
body?
A
Has
someone
tested
this
and
then
someone
else
would
say:
yeah
I
tried
it.
It
did
this
and
this
and
this
and
then
essentially
people.
Some
of
you
might
know
this
as
trip
reports,
it's
essentially
a
form
of
like
very
anecdotal
data
collection,
but
I
found
this
form
of
like
open
source,
drug
development
really
really
fascinating,
and
at
the
same
time
then
I
began
looking
at
like
the
larger
macroeconomic
landscape
of
farmer
and
because
I
started
asking
myself
well.
Why
are
these
people
online
in
the
first
place?
A
This
data
is
extremely
well
guarded.
It's
typically
only
released
like
every
two
or
three
months,
typically
only
released
every
two
or
three
months,
and
when
the
data
is
released,
positive
and
negative,
the
the
stock
typically
does
in
a
5x
or
it
does
money.
Eight
minus
80
in
a
day
which
is
actually
really
inefficient.
A
If
we
think
about,
if
we
think
about
how
markets
work,
it's
like
this
fundamental
information,
asymmetry,
but
furthermore,
most
biology
companies
actually
only
have
an
incentive
to
share
positive
data,
so
a
biotech
company
could
be
generating
100
studies
on
a
specific
compound,
and
two
of
them
are
positive
and,
let's
say
eight
of
them
were
inconclusive
and
90
90
of
them
were
negative.
They
would
only
show
the
two
that
are
positive,
because
you
typically
wouldn't
want
that.
A
What
to
other
people
to
know
that
what
you're
developing
actually
isn't
working,
but
in
the
context
of
science,
this
is
extremely
inefficient.
So
in
science
today,
there's
there's
this
problem
called
the
reproducibility
crisis
that
is
actually
quite
hard
to
reproduce
other
people's
other
people's
data
sets
that
have
generated
so
just
keep
going:
okay,
okay
and
so,
as
I
began
looking
into
these
companies.
A
You
have
to
remember
that
really
up
until
the
80s
and
90s
open
source
was
not
a
thing
and
actually
famously
Microsoft
called
open
source
software.
A
cancer
many
many
years
actually
actively
tried
to
sue
the
Linux,
Foundation
and
Pharma
today
or
like
biotech
and
actually
much
of
science
still
works
like
open
source
in
the
80s
and
90s.
A
A
Foreign
still
not
look
at
that,
and
so,
as
I
began,
getting
more
and
more
into
this
I
kind
of
realized
that
there's
a
fundamental
opportunity
here
to
create
a
much
more
open
and
shared
system
through
the
use
of
web3
Technologies,
because
the
fundamental
difference,
often
in
science
and
in
software,
is
that
science
is
is
in
meat
space.
It
exists
in
the
real
world,
and
so
you
can't
just
as
easily
as
easily
replicate
it
as
you
can.
A
In
other
Industries,
so
here
today,
we
will
we're
going
to
look
at
what
are
the
problems,
definition
and
goals
of
the
DSi
community
in
space
as
a
whole.
We're
going
to
look
a
little
bit
about
what
we've
accomplished
so
far,
specifically
by
going
into
one
specific
one
specific
use
case,
we
want
to
look
at
where
the
whole
Space
is
going
and
the
different
Lego
blocks
that
are
emerging
and
then
essentially
quickly,
move
into
Workshop
sessions
and
different
breakout
groups
to
explore
specific
building
blocks
that
have
emerged
in
the
in
the
D
side.
Space.
A
So
DSi
has
actually
only
existed
for
around
one
year.
It's
a
very,
very
new
phenomenon,
and
the
goal
for
this
Workshop
today
is
also
to
essentially
help
Define
a
future
roadmap
of
where
the
space
is
going
and
and
how
we
can
build
Technical
Solutions
to
essentially
enable
the
next
generation
of
design
developers
to
build
permissionless
open
systems
that
that
can
really
serve
future.
Generations
I
asked
briefly
before
who
knows
about
video
dial,
but
it
would
be
really
interesting
actually
to
know
who,
maybe
in
the
audience
actually
has
a
scientific
background.
A
A
A
A
Big
shout
out
to
a
team
called
ultra
rare
bio
if
you
want
to
follow
them
for,
like
updates
around
the
design
space,
this
overview
was
actually
created
in
I.
Think
in
May,
so
I
think
by
now
already
there's
a
whole
range
of
new
projects,
downs
and
systems
that
have
emerged
that
are
actually
not
not
on
here,
but
just
to
see
how
quickly
the
space
is
moving
and
as
any
kind
of
new
industry
emerges.
A
One
of
the
most
important
things
is
to
avoid
redundancy
and
if
you
maybe
some
of
you,
remember
how
the
whole
defy
space
and
D5
Community
came
into
being.
It's
really
through
building
open,
interoperable
Lego
blocks
that
we
can
all
build
on
together,
and
so
the
biggest
thing
that
you
actually
want
to
avoid
in
the
early
development
of
a
of
a
space
like
this
is
yeah
redundancy
and
you
want
to
enable
permissionless
interoperability
permission.
This,
for
example,
means
not
introducing
friction
in
the
use
of
services.
Permissionness
means
building
in
an
open
source
way.
A
Because
what
now
that
we
like
in
building
out
the
design
space,
we
should
really
ensure
that
we're
not
kind
of
making
the
same
mistakes
as
the
the
industries
and
people
that
came
before
us,
and
it's
tempting
to
do
so,
and
it's
tempting
to
do
so
because
actually
creating
friction
between
systems
is
the
way
that
most
Industries
actually
capture
value.
Today,
it's
about
introducing
them
to
learn,
and
so
I
represent
an
organization
called
molecule,
and
this
is
also
something
that's
really
important
to
us
like.
How
can
we
enable
open
permission
of
systems?
A
A
And
if
we
manage
to
build
those
Lego
blocks
in
the
right
way,
then
I
already
think
in
two
years
we
won't
in
two
years
we
won't
have.
We
won't
have
80
organizations,
but
we'll
probably
have
like
two
thousand.
This
is
essentially
what
what
would
happen
in
in
the
web
3
space
when
D5
came
up
in
probably
in
2018-19
I.
Remember
there
being
like
maybe
two
three
four
five
D5
applications.
A
They
were
extremely
early,
but
if
some
of
you,
for
example,
remember
maker
down,
would
then
launch
or
not
remember,
but
no
maker
down
who
launched,
cdps
and
die
so
die
essentially
was
a
building
block
that
enabled
the
the
emergence
of
a
huge
amount
of
default
applications?
And
that's
that's
one
way
to
think
so.
Science
today
is
full
of
problems.
Funding
in
science
is
incredibly
difficult.
It's
highly
competitive,
it's
very
asymmetrically
distributed.
A
Often
only
goes
to
the
best
universities,
it
goes
to
scientists
that
have
a
lot
of
academic
pedigree,
it's
very
political
to
get
funded
and
there's
some
really
interesting,
Insight
that
actually
most
scientists
today
would
change
their
topics
or
their
field.
If,
if
funding
was
not
a
concern,
so
almost
like
scientists
that
they
have
to
be
extremely
opportunistic,
they
can't
often
actually
work
on
what
they
want
to
work
on.
They
can't
actually
work
on
their
feces.
They
often
have
to
just
chase
the
money.
A
So
one
of
the
first
researchers
that
we
worked
with
that
molecule
and
also
one
of
the
the
first
researchers
to
get
funded
through
Vita
Dao
gave
us
a
famous
quote,
which
was
that
he
spends
80
of
his
time.
Fundraising
and
20
of
the
time
doing
all
the
research,
and
so
fundraising
in
this
context,
actually
means
getting
grants
from
different
different
institutions.
A
Then
the
second
thing
is
replication.
I
gave
this
example
earlier
in
with
biotech
companies,
but
much
of
science
today
is
not
reproducible,
so
someone
will
will
say,
hey
here's,
a
study,
I
got
the
following
outputs
and
then
you'll
try
to
run
the
same
experiments
and
not
get
the
same
answers.
So
how
do
we
get
there?
A
Often
you
have
you
have
competition
for
the
same
grants
and
then
there's
an
issue
with
essentially
like
scooping
each
other's
work.
So
it's
also,
we
don't
have
a
system
yet
today,
where
there's
a
lot
of
scientific
Integrity
actually
between
different
scientists
and
then
a
last
problem
is
that
science
today
is
still
really
inaccessible.
A
Much
of
important
scientific
literature
lives
really
behind
paywalls.
It's
not
it's
not
open
source
and
science
is
often
to
many
people
still
not
very
accessible.
If
we
think
that,
actually
before
any
before
the
whole
nft
art
craze,
I
never
felt
that
art
was
very
accessible
to
me.
It's
like
quite
a
complex,
actually
process
to
go
into
a
gallery
to
figure
out
what
you
like
to
like.
It's
art
wasn't
very
accessible
for
nfts,
but
so
I
think
web3
actually
has
the
potential
to
make
signs
much
more
accessible
to
the
to
the
broader
population.
A
And
a
lot
of
these
problems
that
we
actually
face
in
the
scientific
Community
are
the
same
problems
that
we
have
in
other
Industries.
Today
they
stem
from
centralizing
authorities,
so
funding,
for
example,
is
largely
distributed
through
governments
or
it's
largely
distributed
through
very
powerful
large
private
corporations
and
decentralizing
authorities
essentially
affect
each
part
of
the
scientific
value
flow.
Another
example
is
the
publishing
houses
that
essentially
control
much
of
how
what
is
actually
published.
A
So
if
a
publisher
doesn't
want
to
doesn't
want
to
publish
your
research,
it
may
just
mean
that
it
actually
never
never
gets
disseminated
to
a
much
broader
audience,
and
so
this
is
what
has
to
what
we've
well.
We
have
to
start
changing,
move
away
from
decentralizing
authorities
that
actually
govern
access
to
science
and
govern
Truth
and
move
into
a
much
more
open
scientific
system.
B
A
A
Let's
Build,
a
Better
Planet
like
Yay,
unfortunately
like
like
Goodwill,
doesn't
pay,
and
unfortunately
we
live
in
a
very
capitalistic
and
profit-oriented
system.
It's
actually
the
most
interesting
application
of
web
3
I
think
today
it
has
really
been
creating
incentive
machines,
incentive
machines
that
fundamentally
alter
people's
behavior
and
so
I
think
a
fundamental
thesis
for
us.
A
It
was
that
the
reason
open
science
has
not
succeeded
is
because,
because
there's
no
incentive
on
it
and
for
taking
this
example
that
we
had
earlier
with
a
biotech
company
that
actually
only
hasn't
sent
us
to
publish
positive
data,
but
not
the
negative.
If
we
now
had
open
public
markets
as
we
do
in
the
crypto
space,
for
example,
if
I
you
can
make
an
analogy
that
if
I
find
a
bug
in
a
crypto
Network,
that's
like
open
source
research,
so
actually
crypto
networks
are
relatively
open
source.
A
So,
if
I
discover
a
bug,
data
is
actually
now
valuable,
negative
information.
So
that
could
be
like
this
crypto
network
is
flawed
and
now
I
have
two
options:
I
could
I
could
hack
it
and
stand
to
benefit
from
that
and
through
that
actually
I'm,
revealing
that
this
code
was
fundamentally
flawed,
which
is
actually
valuable
to
society.
It's
like
this
was
actually
flawed
or
I
could
I
could
also
just
ping
the
team
and
tell
them
hey
guys.
Your
code
is
buggy.
You
should
fix
this
ASAP
now.
A
A
So
what
if
science
is
decentralized?
Maybe
first,
let's
ask
the
question
of:
why
is
decentralization
so
important
in
decentralized
system,
users
can
participate
in
a
trustless
system,
so
you
don't
need
to
trust
a
middleman
I,
don't
need
to
trust.
A
publishing
house,
for
example.
I,
can
trust
other
participants
in
the
system.
A
F
A
Yeah
another
one
is
just
like
avoiding
censorship,
resistance,
avoiding
censorship,
resistance,
Fosters,
a
much
more
open
culture,
and
the
last
point
is
really
enabling
enabling
global
global
collaboration.
So
what
is
the
why?
What
and
how
of
design?
So
why
are
we
doing
this?
We're
doing
this,
to
build
an
open
science
movement
and
to
make
science
more
collaborative
and
make
it
accessible
and
open
to
everyone
like
if
you're,
a
promising
scientist
in
Nairobi,
you
should
have
the
same
opportunities
and
chances
as
a
promising
scientist
at
Harvard
today.
A
That
is
not
the
case
in
the
same
way
that
if
you're
a
developer
on
ethereum
I,
don't
really
care
if
you're
in
Nairobi
or
in
Cape
Town
or
in
in
Boston,
does
make
a
difference.
The
same
thing
should
apply
for
science.
What
are
we
doing?
We're
building
a
Global
open
alternative
to
the
current
scientific
system
that
anyone
can
participate
in
so
equal
access
to
anyone
equal
opportunity?
A
If
you
have
a
promising
actually
Vincent
I
love
that
that
example,
that
you
typically
give
around
around
getting
funded
by
a
Dao
as
a
young
researcher,
you
could
be
in
a
16
year
old,
whiz
kid
sitting
somewhere
having
a
great
idea.
Looking
for
funding
in
the
current
scientific
system,
you'd
never
get
funding,
there's
zero
credibility,
zero
trust
to
actually
receive
funding
from
a
reputable
institution,
but
with
these
dials
that
are
emerging
like
age,
doesn't
really
matter
anymore.
A
A
So
what
design
verticals
have
emerged
because
the
scientific
field
is
extremely
broad,
so
the
area
that
this
has
currently
targeting
and
attempting
to
disrupt
one
is
funding
of
data
IP
and
impact,
which
is
a
huge
field.
So
what
we're
essentially
trying
to
enable
is
Foster
and
more
democratic
funding
mechanisms
that
enable
communities
to
form
and
govern
impact
or
novel
forms
by
P.
A
Another
big
vertical
is
publishing
so
having
transparent,
Open
Access,
publishing,
with
aligned
incentives
for
all
participants
having
incentivized
peer
review
Systems
for,
for
example,
the
third
one
is
Dows
and
research
on
governance
over
these
research
assets,
so
dials
present
an
entirely
new
way
of
organizing
researcher
or
patient
involvement
and,
for
example,
clinical
trials.
This
has
never
been
possible
before,
if
you're
a
patient
today,
you
you
have
no
absolutely
no
choice.
What
lands.
What
like
what
comes
onto
the
market?
You
have
no
choice
over
the
price.
A
It
might
be
in
life-saving
medicine
that
you
need
every
day
to
survive.
You
have
no
influence
on
the
price
on
access,
whether
it
is
actually
the
right
medication
yeah
and
neither
do
researchers.
So
we
have
this
very
long
drug
development
process,
but
we've
removed
the
course
stakeholders
from
that
process
and
another
one
is
identity
and
reputation
systems
for
academic
credentialing.
So
how
do
we
actually
trust
scientists
in
these
different
systems?
A
E
A
A
But
of
all
of
these
areas
where
we
currently
seeing
the
most
traction
is
funding
an
IP,
because
it's
like
it's
relatively
simple
today,
I
think
to
facilitate
funding,
use
cases
through
web3
technology.
I
think
it's
still
much
harder,
for
example,
to
to
facilitate
Identity
or
reputation
systems,
303.
A
foreign
ticals
in
in
funding
in
IP.
So
we
have
retroactive
public
goods
funding.
Some
of
you
may
have
participated
or
even
benefited
from
the
recent
DSi
Bitcoin
route.
So
that
was
a
great
a
great
example
of
that.
The
other
one
is
quadratic
funding
having
a
fair,
more
democratic
way
to
bounce
actually
allocate
funding
to
projects.
A
third
one
is
having
Dows
and
tokenized
incentive
structures
such
as
we
did
that
and
the
fourth
one
are
IP
nfts,
which
are
new
form
of
of
on-chain
native
IP
and
data
ownership,
foreign.
A
A
A
Let's
go
deep,
my
goal
like
yeah,
whatever
yeah
the
only
thing
I
want
to
avoid-
is
that
we
prime
it
too
much
about
this
one
use
case
because
there's
so
many
other
use
cases.
But
what
is
interesting
about
looking
at
funding
in
IP
and
specifically,
what
would
we,
as
molecules
have
developed,
which
is
the
ipn
ft?
Is
that
it's
already
very
applicable
in
this
theoretic?
A
But
so,
if
we
look
at
one
of
the
like
the
fundamental
problem,
spaces
of
how
does
innovation
and
biotech
research
actually
work
today,
so
you
have
Innovation
emerging
at
the
fringes
of
an
organization
and
then
in
most
organizations,
Innovation
is
driven
through
a
funnel
and
then
essentially
you
curate
ideas
as
they
emerge
in
systems
and
eventually
something
goes
into
a
market.
So
you
have
idea
generation,
you
define
the
project
and
it
moves
through
this
funnel
and
you
can
actually
map
the
same
process
to
the
entire
drug
development
pipeline.
A
Imagine,
instead
of
every
company
having
this
funnel
by
themselves
and
and
like
we're,
essentially
investing
so
many
resources
on
a
global
scale
to
try
to
achieve
the
same
things?
Wouldn't
it
be
much
more
efficient
if
we
had
a
giant
open
funnel-
and
this
is
essentially
what
we
could
build
with
red
free-
and
you
can
imagine
each
of
these
little
dots
are
now
individual
research
projects
or
individual
individual
assets
driving
through
this
funnel,
and
why
is
it?
A
Why
is
it
that
way
and
the
reason
actually
behind
that
everyone
is
doing
their
own
thing
is
because
we
have
something
that
called
the
patent
system
that
fundamentally
uses
IP,
but
patents
are
really
Legacy.
Legal
physical
assets
patterns
are
literally
often
still
in
most
organizations
boxes
of
papers,
which,
if
you
think
we're
in
2022,
is
absolutely
mind-boggling.
It's
somewhat
ridiculous
that
we're
using
an
extremely
bureaucratic
and
outdated
IP
system
that
makes
IP
very
hard
to
enact
it's
often
much
too
expensive
to
claim
IP
in
the
early
stages.
A
A
It's
actually
because
the
entire
Innovation
System
that
we've
built
around
them
is
is
really
inefficient,
and
so
there's
something
called
the
valley
of
death,
which
typically
happens
here
so
actually
most
of
the
world's
Innovation
never
even
enters
like
enters
further
stages,
which
is,
if
we
think
about
scientific
progress,
is
really
it's
really
a
shame.
It's
like
there's
so
much
good
good
signs
that
never
sees
the
light
of
day
and
if
we
think
about
data
and
software
data
and
software
today
is
completely
virtual.
A
But
if
you
think
Back,
40
years
ago,
companies
literally
had
still
had
like
entire
floors,
with
filing
cabinets,
pulling
hundreds
of
people
to
sort
through
those
data
sets.
This
is
an
example
I
really
like
using
the
screenshot
was
taken
about
a
week
ago.
This
is
the
current
state
of
the
art
of
the
US
PTO
patent
search
system.
A
That's
literally
how
it
looks
in
2022
and
the
only
other.
The
only
alternatives
to
this
system
are
paying
really
expensive,
like
legal
software
to
essentially
to
essentially
search
and
discover
patents.
So
if
we,
if,
if
I,
was
someone
who
was
like
hey,
let
me
look
for
interesting
cancer.
Research.
That's
been
patented
and
I'm
like
trying
to
find
something
in
here
like
this
is
this
is
what
I'm
supposed
to
use
from
the
government,
of
course,
there's
better
system
than
this,
but
they're
typically,
proprietary
I'd
have
to
pay
for
them
yeah.
C
A
E
G
A
So
what
we
have
a
system
today
that,
rather
than
the
best
science
winning
we
really
have
Revenue
drivers
that
dominate
that
dominate
medicine,
so
at
molecule
we've
really
spent
almost
the
past
four
years
asking
ourselves.
What
could
a
better
system
look
like
for
this
and
we're
trying
to
build
towards
an
open
market
for
iip,
so
kind
of
trying
to
reimagine
the
system
and
making
it
much
more
transparent?
A
And
one
fundamental
thesis
that
we
have
is
that
most
of
the
world's
potential
scientific
Talent
remains
untapped,
and
so,
for
example,
if
we
think
through
what
happened
in
in
the
nft
market,
the
nft
market
for
for
artists
and
now
for
music
fundamentally
has
changed.
How
we
interact
with
art
and
fundamentally
has
enabled
a
different
Creator
economy
for
artists,
and
so
what?
If
we
enable
a
creative
economy
for
scientists
to
really
help
helping
the
best
Innovation
across
the
world
rise
to
the
top?
A
So
what
is
an
iPhone
ft?
Ipn
ft
is
first,
it's
a
legal
contract
and
a
real
world
license
that
is
tied
to
research
or
data.
So
it's
a
legal
contract
that
now
takes
IP
out
of
an
organization
or
out
of
University
and
attaches
that
to
an
nft.
The
second
is,
it
has
a
storage
layer,
so
you
have
a
decentralized
permanent
data
storage
with
public
and
private
data
repos.
So
almost
now
imagine
this.
This
nft
is
like
simple
simplest
way
of
saying
it.
A
It's
like
has
like
a
decentralized
Google
Drive
attached
to
it,
where
the
owner
can
now
provide,
read
and
write
permissions
to
anyone
that
wants
that
it's
transactable
in
the
same
way
that
an
nft
is
transactable.
It's
discoverable
through
public
metadata
around
that
nft,
so
I
can
now
publicly
on
change,
start
searching
through
the
metadata
of
these
assets
and
then
fundamentally
and
I
think
this
is
the
most
exciting
part
you,
the
IP
now
becomes
programmable
and
composable.
A
That
means
you
have
governance.
You
have
fractionalization
if
you're
interested
in
actually
ipfg
fractionalization.
We
have
one
of
our
someone
from
our
legal
team.
Here
we've
developed
a
new
framework.
That's
called
the
friends
framework
because,
fundamentally,
what
you
need
to
avoid
is
making
any
of
these
assets
like
Securities,
because
then
they
don't
become
transactable
in
web
free
and
they
don't
become
Lego
blocks,
at
least
for
now.
You
can
have
programmatic
royalties
or
pay
for
Success
models.
A
What
does
this
kind
of
look
like
from
a
kind
of
from
an
online
perspective?
So
you
have
a
real
legal
contract.
That's
mapped
onto
a
smart
contract
that
then
maps
to
metadata
that
is
stored
in
our
wave,
and
then
you
have
encrypted
and
private
patent
data
that
now
fundamentally
protects
the
IP,
and
this
latter
part
you
can
open
up.
You
can
open
source
it
or
you
can
keep
it
private
one.
A
One
really
one
big
thing:
that
Riri
does
it's
actually
really
hard
to
do
open
science
in
a
field
like
biotech
because
we
began,
we
began
working
with
an
organization
called
The,
Open,
Source,
Pharma
Foundation.
This
is
in
in
2019
and
essentially
what
they
do.
Is
they
create
public
GitHub
repos
for
open
source
drug
development
that
they're
doing
so?
A
A
However,
I
think,
as
thousands
and
communities
for
example,
get
much
larger,
you
can
actually
move
more
in
into
impact
driven
development,
so
maybe
so
to
close.
The
session
ipnfts
in
our
view,
are
really
a
first
composable
web
3
Lego
block,
so
they
can
be
transacted
like
nfts
and
applied
for
funding.
Dows
can
now
build
portfolios
of
research
of
ipn
FTS.
So
we
have
this
new
phenomenon,
a
bio
dowels
that
have
been
emerging,
which
are
Dows
that
are
now
focused
on
different
therapeutic
areas.
A
So,
since
we
design
emerged,
we
now
have
a
dial
focusing
on
Neuroscience
there's
a
dial
focusing
on
psychedelic
research.
There's
a
doubt
focusing
on
women's
reproductive
Health.
There's
a
dial
focusing
on
hair
loss,
there's
another
doubt
focusing
on
synthetic
biology,
and
all
of
these
dials
can
now
use
the
ipnft
as
a
basic
building
block
to
build
an
on-chain
portfolio
of
IP.
A
Nfts
can
also
be
fractionalized
kind
of
and
be
inserted
as
design
Lego
blocks.
You
could
imagine
an
nft
and
an
ipn
ft
being
fractionalized
and
then
those
fractions
going
into
different
on-chain
liquidity,
pools,
they're,
fascinating
new
mechanisms
where
the
the
the
fees
that
are
now
being
generated
through
these
liquidity
pools
can
actually
be
used
to
fund
the
research
as
well.
So
everything
that
has
been
built
in
D5
for
the
past
two
years
three
years
can
now
also
be
cross-applied
to
design.
A
For
example,
also,
data
access
can
now
be
granted
by
multi-signature
wallets
and
we
really
only
beginning
to
scratch
the
surface
of
what
is
possible
here
now,
one
of
our
core
goals
and
molecule
for
the
next
for
the
next
two
months.
Three
months,
it's
actually
fully
open
sourcing.
This
first
version
of
the
ipfg
protocol
to
enable
anyone
to
start
playing
around
with
it
and
essentially
just
tinkering
around
with
it,
because
we
don't
actually
know
yet
how
many
applications
this
this
can
be
used
for.
A
The
ipnft,
for
example,
combines
what
I
would
say
is
a
transaction
layer
and
a
data
storage
layer,
but
it
doesn't
actually
touch
any
of
the
other
layers
and
so
now
we're
slowly
moving
into
the
the
workshop
part
I
think
Tyler
just
left,
so
the
goals
for
this
Workshop
today
is
essentially
now
to
look
at
both.
What
Lego
blocks
do
we
have
and
to
look
at
how?
How
are
they
matched
with
different
design
verticals?
A
A
So
the
goal
of
this
Workshop
will
be
to
really
explore
how
we
can
how
decentralized
science
can
improve
the
process
of
funding,
doing
and
disseminating
science
through
the
use
of
decentralized
systems.
So
now
we're
going
to
look
at
each
of
these
different
elements
and
yeah,
since
you
start
workshopping
them
Vincent
yeah.
A
So
the
form
of
the
workshop
will
be
that
we
now
have
a
breakout
session
for
about
40
minutes
where
we
can
gather
around
these
different
topics.
We
also
have
multiple
members
from
leading
organizations
from
these
different
areas.
In
the
room
with
us
today,
we
can
then
do
like
breakout
pitches,
where
people
from
that,
if
not
formed
through
these
different
teams,
can
essentially
pitch
their
ideas
and
then
we
we
can
all
discuss
them
together.
A
I
G
F
Yeah
so
I
think
the
thought
was
basically
there's
these
four
high
level
verticals
that
we've
just
that
we
sort
of
identified,
but
obviously
this
can
be
opened
up
much
more
broadly,
depending
on.
If
someone
has
an
individual
like
interest
that
they
want
to
tackle,
that
isn't
met
by
the
list
that
we
have
here.
But
so
we
can
look
at
things
in
the
context
of
funding
an
IP
which
would
be
things
such
as
like
basic
science,
for
example,
grad
funding,
translational
research,
productizing
medicines,
all
the
way,
I'm
taking
a
very
large
Sciences
approach.
F
F
I
think
functionally.
It
would
make
most
sense
to
sort
of
organize
around
either
case
that
we
wanted
to
join,
which
could
be
like
creating
a
fast
grants
mechanism
for
basic
science,
research
funding,
ethereum
or
creating
a
a
reputation
system
for
D
side
dials
as
examples
or
we
could
also
look
at
just
a
particular
problem.
Space.
F
E
F
F
E
F
But
you
can
open,
you
can't
open
the
dock
here,
no
worries
yeah,
so
you
can
scan
this
with
your
phone
and
we've
basically
prepared
a
document
that
talks
a
little
bit
about
some
of
the
goals
of
the
workshop
I
think
there's
a
couple
of
different
ways
that
we
can
approach
this.
The
first
is
really
just
to
facilitate
robust
discussions
that
are
currently
looking
at
like
what
is
the
status
quo
and
the
Sciences
today.
F
So
if
we
look
at
something
like
funding,
for
example,
or
something
like
publishing,
what
is
functioning
really
well
in
the
current
system,
what
is
not
functioning
so
well
in
the
current
system
and
basically
identifying
the
sort
of
like
where
we're
succeeding
and
where
we're
not
and
then
begin
to
think
about
what
aspects
of
the
current
system
we
want
to
migrate
into
this
novel.
Let's
say:
DSi
focused
architecture.
F
What
we
think
needs
to
be
upgraded
and
what
can
go
and
then
they
actually
begin
thinking
through
Maybe
by
Chopin
show
of
hands
how
many
developers
are
in
the
room
or
technically
oriented
folks.
Let's
say
you
don't
need
to
necessarily
really
be
a
developer,
so
yeah
maybe
an
interesting
way
to
organize.
If
we're
capable
of
doing
this
would
be
to
in
a
perfect
world,
this
might
be
challenging,
but
we
would
have
like
one
developer
per
table.
F
F
Does
that
make
sense?
Do
we
want
to
maybe
start
by
like
we
can
also
throw
up
a
couple
prompts
or
like
use
cases
that
we
want
to
tackle.
People
could
raise
their
hands
and-
and
we
could
also
just
walk
around
and
try
to
organize
self-organize
into
different
topics.
That's
extremely
difficult
to
read,
but
yeah
totally.
There's
a
lot
of
flexibility.
I.
Think
from
this
point
in
how
we
actually
how
we
actually
run
this,
but
I.
F
Think
the
the
prime
takeaway
or
the
main
thing
that
we
should
be
working
towards
is
basically
just
trying
to
create
a
clear
road
map
to
solving
some
of
the
problems
that
we've
identified
together
in
these
verticals.
Does
that
make
sense
any
questions
cool?
Would
it
make
sense
to
start
by
actually
organizing
a
bit
based
on
expertise
so
like
like
devs
can
get
together?
Product
people
can
get
together,
UI
ux
people,
scientists
can
get
together,
and
then
we
can
actually
from
that
choose
like
organize
into
actual
groups
and
tables
for
specific
problems
or
where.
F
E
A
F
Would
love
to
think
about
a
novel
reputation
system,
specifically
for
DSI,
so
looking
at
the
current
faults
with
impact
factor
and
basically
how
we
deal
with
academic
credentials
and
think
about
what
the
V2
of
this
looks
like
for
for
DSI?
So,
if
you
want
to
think
about
this
problem,
you're
more
than
welcome
to
come
join
me
at
this
table
to
to
tackle
it.
Okay,.
J
I'm
curious
to
look
at
publishing
from
a
hypertext
perspective
so
like
because
I
see
how
referencing
is
super
old
school
like
you're
publishing
PDFs.
It's
super
hard
to
look
at
where
research
came
from
so
I'm
interested
in
exploring
like
the
web
native
Hypertech
system
and
migrating
that
to
how
research
could
look
like
in
an
interactive
web
environment.
A
K
K
L
A
E
A
A
A
If
anyone
can
see
I
think
I,
misplaced,
the
mic
somewhere
or
maybe
the
support
people
took
it,
but
it
should
be
somewhere
and
yeah,
so
just
transcribe
kind
of
that
main
outputs
that
you're
also
going
to
present
into
this
doc
so
that
we
can
share
it
with
the
world
and
the
community.
After
this,
that
would
be
really
awesome.
Okay,
who
wants
to
go
first.
F
So
we
were
looking
at
a
scientific
reputation
system
and
looking
first
at
how
our
current,
like
scientific
reputation
system
functions.
So
we
first
mapped
the
current
system
out
into
two
verticals.
One
would
be
formal
credentials
and
other
would
be
sort
of
informal
reputation
and
formal
credentials
are
things
that
are
verifiable,
measurable
and
somewhat
quantifiable.
These
are
things
like
academic
affiliation,
degree
impact
factor,
H
score
pedigree
citations,
for
example,
and
funding
sources
and
then
there's
more
sort
of
informal,
more,
let's
say,
qualitative
reputation,
things.
F
This
is
like
social
media
and
press
collaborators
and
peers,
who
you
know
political
affiliations,
hype,
your
ability
to
influence
others,
and
we
mapped
out
some
pros
and
cons
in
each
of
these.
If
you
want
to
like
look
at
these
in
detail,
you're
you're
more
than
welcome
to
they're
they'll,
be
in
the
dock,
but
just
as
like
a
high
level
example,
without
going
into
excruciating
depth
on
each
of
these
things
like
academic
affiliation
can
demonstrate
or
attract
quality.
They
could
signal
trustworthiness.
They
can
be
associated
with
specific
areas
of
expertise.
F
They
could
act
as
sort
of
shelling
points,
but
on
the
other
side
they
can
create
inequality.
They
can,
for
example,
Foster
sort
of,
like
certain
reinforcement
patterns
create,
like
Legacy
students,
there's
a
bunch
of
problems
in
sort
of
fostering.
Sorry,
this
the
stock
is
moving
in
real-timeism
reading
it
I'll
just
talk
through
it
rather
I.
Think
I
can
do
it
from
memory.
F
Their
ideas
are
initially
rejected,
so
we're
basically
trying
to
look
at
in
the
context
of
all
of
these
different
verticals,
whether
they
be
like
verifiable
credentials
or
sort
of
informal
credentials.
What
are
the
sort
of
things
that
we
want
to
bring
over
into
into
DSi?
In
the
context
of
this,
let's
say
new
reputation
system,
and
so
we
did
a
little
bit
of
work
thinking
about
things
like
credentials,
and
these
could
be
represented
by
things
like
Soul
bound
tokens,
for
example.
F
So,
instead
of
just
having
academic
affiliations,
who
want
to
have
things
like
industry,
affiliations,
Guild
affiliations,
Dow
affiliations,
what
are
the
communities
that
you're
associated
with
what
are
the
values
of
those
communities
and
how
do
we
measure
those
I
think
we
also
want
to
look
at
for
people
who
are
involved
actively
in
funding.
How
are
they
making
an
impact?
What
Dallas
and
organizations
are
they
a
part
of?
What
areas
have
they
done?
F
Research
in
what
areas
have
they
may
be
impacted,
and
this
is
also
a
hard
thing
to
measure,
but
I
think
using
impact
certificates
and
actually
pull-ups
in
some
cases,
you
could
begin
to
use
some
of
those
Technologies
to
measure
the
impact
that
somebody's
having.
We
could
also
look
at
things
like
gits
and
like
pull
requests
in
the
context
of
liking
data
becoming
increasingly
but
like,
let's
say,
if
you're
doing
in
silica
work
in
the
context
of
of
biology.
F
You
can
begin
to
look
more
in
real
time
at
how
somebody
is
contributing
data
to
a
certain
research
area
and
began
to
measure
an
impact
that
way
and
there's
also
things
like
measuring
Dow
reputation.
So,
if
I'm,
a
contributor
in
a
Dell,
you
know
am
I
somebody
that
people
are
delegating
boats
to
am
I
somebody
who's
being
rewarded
via
things
like
coordinate,
have
I
been
elected
as
Stuart
and
then
also
looking
at
other
factors
like
value
captured
value
generated,
am
I,
deploying
funding
have
I,
have
I
received
funding
from
certain
people.
F
We
could
also
look
at
like
token
Holdings.
We
could
look
at
how
active
I
am
as
a
governance
contributor
in
a
dial,
but
in
the
end,
there's
all
of
these
sort
of
all
of
these
I
would
say
new
interaction
patterns
that
are
happening
by
the
internet
that
are
actually
producing
a
lot
of
really
really
rich
data.
F
That
is
quite
different
from
how
PSI
science
works
today
and
what
we
want
to
try
to
figure
out
and
where
we
haven't
gotten
to
actually
in
the
context
of
this
short
session
is
really
thinking
about
how
those
things
are
all
weighted.
How
they're,
measured
and
I
think
the
most
interesting
question
here.
If
we
think
about
creating
like
a
holistic
reputation
system
that
would
be
akin
to
something
like
impact
factor,
it's
really
challenging
to
do,
because
I
think
the
needs
of
scientific
communities
are
are
very
different.
F
So,
for
example,
I
might
be
somebody
that
from
a
reputation
perspective
is
a
really
good
developer
or
is
maybe
just
really
good
at
data
collation
and
data
analysis.
How
is
my
reputation
weighed
against
somebody
who
has
maybe
also
publishing
and
also
funding
research
and
so
thinking
about
dynamically?
How
these
systems
interact,
I
think
will
be
a
really
interesting
technical
challenge.
F
One
of
the
things
that
we
were
thinking
about
was
like
if
a
Dao
has
a
certain
set
of
needs,
so,
for
example,
feedadel
might
have
a
need
for
longevity
researchers
that
have
worked
in
X
or
Y
fields
and
have
of,
for
example,
experience
with
certain
assays
and
certain
data
techniques.
That
is
very
different
from
another
organization.
F
And
how
can
we
have
a
system
that
basically
adapts
based
on
the
skill
sets
that
that
individuals
have
so
sort
of
like
everything,
we've
talked
about
taking
a
dynamic
approach
to
this
reputation
system?
That
is
not
one-sided,
meaning
that
it's
not
just
the
impact
factor
of
researcher,
but
the
needs
of
an
organization
juxtaposed
against
the
specific
skill
set
that
someone
has
and
I
think.
F
This
could
be
really
interesting,
because
going
back
to
an
earlier
example
that
you
made
Paul
if
there's
like
a
16
year
old
somewhere
in
the
world,
that
ends
up
being
an
excellent
scientific
reviewer,
because
they
self-taught
themselves,
I,
don't
know
like
biochemistry-
and
you
know,
on
the
internet.
No
one
knows
your
age
but
they're,
making
they're
making
like
comments
on
papers
or
whatever
that
are
really
valued
by
the
community.
We
want
a
way
to
to
measure
that
that
is
like
independent
of
academic
affiliation,
for
example,.
A
A
On
that
note,
thank
you
so
much
for
sharing
that
Tyler.
Could
your
group
also
please
upload
your
doc
into
the
into
the
section
and
then
maybe
I'll
just
go
so
it's
a
bit
buggy
here
cool,
we'll
go
into
tableware
traffic
public
goods
next,
just
because
that's
up
right
now,
okay,
awesome
and
we
have
about.
Maybe
we
have
about
three
minutes
at
the
moment
for
each
for
each
topic.
I
just
want
to
make
sure
that
everyone
gets
a
chance
to
speak
before
they
kick
us
out
of
here.
B
B
There
we
go
yeah,
okay,
so
the
whole
idea
behind
impact
markets
is
to
look
at
funding
public
goods
and
science
as
a
public
good.
So
the
most
important
thing
is
to
look
at
like
how
do
we
value
impact?
That's
the
trickiest
part,
and
then
once
we've
got
that
essentially
the
market,
we
need
to
find
retractive
funding.
B
So
in
this
particular
case
we're
talking
about
we've
got
this
thing
called
the
longevity
prize,
the
Vincent's
sorting
and
we
read
it
through
Bitcoin
and
sort
of
raised,
say
250
Grand,
and
so
we've
got
like
a
source
of
retroactive
funding
available.
Then
the
next
question
is
kind
of.
What
do
we
want
to?
What
sort
of
impacts
you
know
is
is
going
to
be
in
something
that
can
scale.
B
So
you
know
if
the
prize
ends
up
being
10
million
dollars
or
100
million
dollars
or
whatever,
then
you
know,
we've
still
got
impact
being
generated
once
you've
got
that.
Essentially
you
can
do
this
thing
called
you
can
mend
an
ipn
ft
or
a
hybrid
sir
they're
kind
of
similar
Concepts.
But
what
those
do
is
they?
Let
you,
as
somebody
that
can
potentially
deliver
some
impact,
say
you're,
a
scientist
and
you've
got
a
really
great
idea
and
you
want
to
get
funded
and
it's
a
public
good.
B
You
can
mint,
you
know,
there's
ipn,
ffts,
that's
hyperspirate
and
then
raise
money,
basically
from
from
investors
where,
before,
like
you
know,
because
it's
a
public
good,
essentially
there's
no
way
like
under
the
traditional
IP
system
that
you
can
enforce
a
Monopoly
price,
so
yeah
I
keep
talking
about
generic
drugs
and
things
like
that.
So
that's
something
I'm
interested
in
but
which
is
yeah.
Basically,
if
you
can
get
an
off
patent
drug
and
repurpose
it
to
treat
a
new
disease
like
so
ketamine
to
treat
depression.
B
Let's
say
you
know
you
could
actually
create
like
billions
of
dollars
and
and
social
value,
with
quite
a
like
little
bit
of
investment
there
retractive
funding
so
yeah,
so
so
yeah.
Basically,
once
once
you've
delivered
the
impact
whatever
that
might
be
so,
for
instance,
improved
clinical
outcomes
versus
usual
care,
then
you
will
get
the
outcome
payment
under
this,
the
from
the
retracted
funding
and
the
market.
Basically
figures
things
out.
B
So
if
it's
not
enough
funding
like
if
250k
is
not
enough,
you
can
basically
get
philanthropy
to
put
in
the
rest.
So
it's
a
little
bit
like
Bitcoin,
where,
like
you,
sort
of
have
little
donations,
creating
signals
or
little
Investments,
creating
signals
for
a
philanthropic
funder
to
come
in
and
and
find
the
rest.
So
yeah.
I
I
One
of
our
ideas
was
in
a
more
like
crowdfunding
sense
that
you
don't
have
to
buy
it
for,
say
a
hundred
thousand,
but
you
can
put
in
a
hundred
bucks
or
a
thousand
bucks
and
get
like
almost
like
a
small
share
in
this
impact
certificate,
which
could
be
just
like
an
IBN
ft,
which
could
then
be
basically
put
into
like
a
million
pieces,
for
example.
And
then
it's
almost
like
also
like
a
pop
and
kind
of
like
collectible,
because
you
show
that
you
funded
research.
I
So
so
it
gives
you
not
only
potentially
like
the
price,
but
also
almost
like
some
status
as
being
a
science
funder
you're
doing
like
impact.
So
it's
kind
of
like
also
a
bit
of
philanthropy
and
it's
almost
like
a
collectible.
So
you
can
like
collect
all
the
little
research
you
from
this.
But
it's
also
like
a
prediction
Market,
because
you
can
potentially
sell
it
so
like
as
it
could
hit
the
price
it
could
also
grow.
In
value,
so
it's
almost
like
you're
signaling.
B
B
G
M
M
How
do
we
get
gather
people
not
just
for
collecting
surveys,
not
just
for
conducting
surveys,
but
also
like
how
do
you
get
other
people
to
participate
in
clinical
trials
and
all
that
falls
under
like
a
a
a
a?
We
need
sort
of
like
a
database
of
sorts
which
can
store
metadata
and
allow
people
to
like
ask
questions
to
this
entire
population
and
see
narrow
them
down
to
specific
segments,
and
so
that
could
be
like
a
distributed
database,
for
example.
M
Maybe,
and
and
then
you
have
to
apply
like
operations
on
that
distributed
database
to
find
your
target
audience,
and
so
other
things
we
talked
about
was
like
how
do
we
in
throughout
the
scientific
process?
You
also
need
to
like
I
didn't
before
you
even
start
research.
You
need
to
identify
what
is
a
problem
that
actually
needs
to
be
solved,
and
so
in
in
order
to
identify
a
real
issue
that
needs
to
be
solved.
M
So
then,
how
do
you
address
the
problems
with
the
unhealthy
people,
like
maybe
yeah
like
like,
because
we
do
actually
need
to
solve
the
problem
for
unhealthy
people
in
a
way
yeah?
So
what
is
the
right
thing
to
fund?
Is
the
there's
a
problem
in
yourself
also
and
then
yeah
more
things
on
yeah.
So
can
you
scroll
down.
M
M
Yeah
like
so,
we
talked
about
Cloud
labs
and
how
can
like
Cloud
labs
and
like?
How
can
we
conduct?
How
can
we
have
like
databases
of
people
of
labs
or
like
facilities
that
can
help
conduct
research
and
then
also
like
even
currently
web,
and
then
also
another
thing
is
like
throughout
the
signing
process.
You
also
need
to
make
sure
that
your
experiments
are
conducted,
trust
in
a
trusted
manner.
M
So
how
can
we
have
chains
of
trust
that
go
that
go
from
like
from
the
ground,
maybe
like
from
the
individual
level,
all
the
way
to
back
to
the
researcher
and
then
beyond?
The
research
actually
yeah
and
I
think
one
final
thing
we
touched
on
is
like:
how
do
you
duplicate?
How
do
you
duplicate
experiments
or
studies
conducted,
and
that
will
usually
involve
like
open
source
studies
and
being
able
to
query
these
studies
so
we'll
need
solutions
to
like
catalog
and
index
studies
already
conducted
in
the
past
and
yeah?
M
There's
a
lot
of
problems
in
I.
Think
in
in
summary,
there's
a
lot
of
problems
throughout
the
scientific
process
that
requires
individual
tools
and
race,
two
very
specific,
open
tools
that
are
globally
accessible
and
in
order
to
be
able
to
re
increase
the
efficiency
of
the
way
the
scientific
process
is
conducted.
Yeah
I
think
that's
summary
of
what
we
would.
A
J
Thank
you
so
we're
the
publishing
team,
I
guess
for
us.
It's
it's
really
a
question
of
building
connective
tissue
or
also
before
I
start
with
also
the
penguin
team,
because
we
have
a
penguin
on
our
little
thing
here,
but
but
the
real
real
question
we're
trying
to
solve
is
that
of
like
connective
tissue
and
really
linking
everything
together
and
the
big
question
at
the
top
is:
how
do
we
amplify
Collective
thinking
within
the
context
of
scientific
discovery?
And
how
can
we
make
that
process
easier
for
people,
and
this
involves?
J
J
So
what
we
kind
of
realized
during
our
discussion
is
that
basically,
what
we're
trying
to
do
is
replace
Publishers,
that's
middlemen
and
come
up
with
with
a
system
that
is
more
decentralized
and
Equitable
for
the
researchers
that
are
involved
and
another
big
problem
that
we
talked
about
was
actually
actually
crypto,
history
and
and
I.
Think
Brewster
kale
had
a
brilliant
talk
on
this
yesterday,
I
did
before
from
the
internet
archive
how
you
can
just
pull
Publications
off
of
the
record,
and
you
don't
want.
J
You
really
want
to
avoid
that,
and
you
want
things
to
be
accountable,
50
100
years
down
the
road.
So
our
solution
is
really
just
to
use
the
existing
technologies
that
already
are
around,
like
our
weave
and
content,
addressing
to
build
connective
tissue
for
linking
between
papers
and
Publications,
and
the
big
sort
of
money
or
like
the
Lego
here
would
be
for
DSI
would
be
some
sort
of
publishing
standard
with
the
associated
metadata.
J
That
will
link
these
papers
together,
whether
that
is
like
referencing,
whether
that
is
like
referring
to
people
who
built
the
system.
The
build,
wrote
the
paper
and
I
think
that's
where
it
kind
of
plugs
into
the
reputation
system
that
the
other
team
presents
earlier,
and
also
we
discussed
like
how
can
we
connect
these
papers
to
the
IP
that
resulted
from
them,
and
we
were
talking
about
how
we
could
plug
that
in
as
well.
J
So
you
could
imagine
visiting
like
a
Wikipedia
site
that
pulls
from
an
RV
backend
and
has
like
really
good
user
interface.
You
could
click
and
see
what
IPS
are
related
to
this.
How
the
reputation
of
these
scientists
who
wrote
this
is
and
like
also
look
at
the
references
by
4
following
the
r
weave
links
and
because
it's
are
we
if
it's
permanent,
you
don't
have
to
like
worry
about
the
data
disappearing.
Any
point
in
time.
J
A
L
Okay,
I
feel
powerful.
Now
so
we
talked
about
decentralized
clinical
trials.
Firstly,
why
would
you
decentralize
the?
How
would
web
3
work
I
think
we
came
to
a
broad
consensus
that,
generally,
generally
speaking,
the
things
you'd
initially
want
to
look
at
would
be
clinical
trials
where
things
weren't
particularly
dangerous,
and
you
can
get
over
the
counter
and
it's
okay
to
ask
the
general
public
to
do.
L
We
also
talked
about
how
you
would
decide
which
trials
to
run
and
why
I
think
broadly,
we
agreed
there
should
be
some
vague
oversights
from
professional
people
in
that.
So
you
don't
do
something
too
dangerous
and
last
we
talked
about,
went
down
a
big
rabbit,
hole
on
incentives,
the
potential
of
micropayments
and
the
pitfalls
of
people
just
taking
the
step
counter
and
attaching
it
to
a
piece
of
string
and
putting
it
in
front
of
a
fan.
Apparently
that
works
quite
well.
L
H
Thank
you,
okay.
So,
on
the
legal
side,
we
worked
on
a
practical
case
and
I
presented
a
problem
to
Jesse.
So
I
worked
for
society
Institute.
We
are
sort
of
perfect
Problem
Child
for
this
eye.
We
are
a
non-profit
organization
that
is
based
in
California
that
has
existed
for
40
years,
doing
science
really
at
the
edge
trying
to
accelerate
science.
That's
way
too
ambitious
or
too
Niche
for
legacy
institution
generally
to
to
feel
comfortable
to
fund.
K
Thanks
Lou,
so
we
only
have
two
two
sets
of
solutions
to
these
two
questions.
One
is:
how
do
you
make
a
dow
from
your
non-profit
that
doesn't
jeopardize
the
Dao
and
its
existence,
and
the
answer
is
well.
We
did
a
Vita
now
a
fair
launch
with
with
no
pre-sale,
then
that
may
Rob
some
people
the
wrong
way,
who
want
to
raise
money
privately
from
investors
before
launching
the
Dow.
K
There
has
to
be
some
kind
of
break
in
that
chain
in
order
to
prevent
the
token
from
having
a
secured
interest
in
the
treasury
of
the
Dow,
in
other
words,
the
token
being
a
security
and
in
that
same
vein,
no
distribution
of
profits
to
token
holders,
and
so
that
leads
to
the
question
of
like
well.
Well,
if
you
can't
distribute
profits
to
token
holders,
token
holders
have
no
direct
claim
on
the
treasury.
Then
then,
what's
the
token
for
right,
how
do
you
reward
people
for
participating
in
this
dial
at
all?
K
And-
and
the
answer
is
in
part,
what
we
do-
a
Vita
dial
and
the
best
example
is
to
look
at
a
university
endowment.
A
university
endowment
makes
Investments
right,
it
makes
money
it.
It
makes
money
for
the
University
and
then
that
money
is
distributed
to
University
administrators,
to
students
through
scholarships
to
making
buildings
to
making
the
university
a
better
place.
K
No
Professor
or
student
has
a
direct
claim
on
profits
that
are
made
from
the
investments
in
the
university
endowment,
but
the
university
grows
and
becomes
a
better
place
and
becomes
a
higher
salaries.
Professors
get
paid.
More
scholarships
are
handed
out
to
larger
degrees,
the
more
money
that
the
endowment
makes.
K
However,
again
no
Professor
has
any
claim
on
profits
that
are
made
from
the
the
university
endowment
and
so
I
encourage
you
to
think
of
your
biotech
Dao
and
the
money
that
it's
making
and
the
treasury
that
it
has
like
a
university
endowment
and
the
structure
of
the
Dow
as
a
non-profit
structured,
almost
like
a
university
and
then
later
with
our
ipn
ft
2.0
protocol
and
the
fractionalization.
That
comes
with
that
into
friends
and
fam
tokens,
which
we
can
talk
about
at
dinner.
H
Thank
you
just
make
listening
and
final
announcements.
Wait,
don't
disconnect
I
put
on
top
of
the
document
so
tonight
in
my
in
partnership
with
molecule
fourth
age
is
foresight,
is
the
hosting
a
decide
dinner
at
tiatro
repeal,
and
so
we
invite
you
all
to
join
and
continue
this
discussion
I've
put
the
perfect
thanks.
H
A
A
If
you
want
to
be
tagged
in
it,
please
feel
free
to
put
your
Twitter
handle
into
the
doc
yeah
and
look
forward
to
maybe
seeing
some
of
you
at
the
dinner
tonight
and
remember:
build
build
Lego
blocks,
build
railroads,
build
roads
that
other
people
can
use
and
that
can
cross
integrate
into
the
community,
because
we
still
have
such
a
big
opportunity
here
to
set
those
Railways
for
everyone
to
yeah
to
interoperate,
which
is
what
open
signs
and
decide
should
all
be
about.
Thank
you
so
much
thing.